Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway
Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side effects, and drug resistance, which poses critical challenges in the clinical setting. Acquired resistance of ELTN r...
Saved in:
Main Authors: | Donglai Chen (Author), Fuquan Zhang (Author), Jinhui Wang (Author), Hua He (Author), Shanzhou Duan (Author), Rongying Zhu (Author), Chang Chen (Author), Lichen Yin (Author), Yongbing Chen (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2018-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
by: Al-Keilani MS, et al.
Published: (2018) -
Synergistic Effects of 2-Deoxy-D-Glucose and Cinnamic Acid with Erlotinib on NSCLC Cell Line
by: Wrood salim Al-khfajy, et al.
Published: (2023) -
Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment
by: Shihui Bao, et al.
Published: (2021) -
Scalable Production and In Vitro Efficacy of Inhaled Erlotinib Nanoemulsion for Enhanced Efficacy in Non-Small Cell Lung Cancer (NSCLC)
by: Gautam Chauhan, et al.
Published: (2023) -
JAK-STAT pathway inhibitors in dermatology
by: Hélio Amante Miot, et al.
Published: (2023)